Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Verseon Claims Major Move In Drug Design, Will Enter Clinic Within A Year

This article was originally published in The Pink Sheet Daily

Executive Summary

The Fremont, California-based company has developed a computer-driven discovery platform that can model drug-protein interactions with unparalleled accuracy but can also generate synthetic pathways for its drug candidates.


Related Content

In Silico Drug Design: Finally Ready For Prime Time?
European Biotech Is “Hot” Again, But Needs Nurturing For Further Growth
Evotec Drug Development Strategy Offers Little Downside, Big Upside


Related Companies